Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palatability of SHP429 in Healthy Adults
NCT02125292Phase 1Completed
- Sponsor
- Takeda
- Start
- Jun 2014
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Salcrozine in ulcerative colitis (UC) (3 arms), sponsored by Takeda. Primary endpoints: Number of Participants With Positive Responses to Palatability Assessment of The Taste of Mesalamine, Number of Participants Who Detected an Aftertaste of Mesalamine and 2 more. Started Jun 2014; status: completed.
02
Drugs
Salcrozine
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT02125292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02125292.